Research And Development

ProQR Therapeutics reported a second quarter net loss of 11.7 million euros, or 0.30 euros per share, compared with a net loss of 7.4 million euros, or 0.23 euros per share, in the same quarter of 2018, according to a press release.

EyePoint Pharmaceuticals reported a second quarter net loss of $11.5 million, or $0.11 per share, compared with a net loss of $34.4 million, or $0.62 per share, in the same quarter of 2018, according to a press release.